Cargando…

Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations

PURPOSE: The aim of this study was to develop a novel busulfan dosing regimen, based on a population pharmacokinetic (PPK) model in Chinese children, and to achieve better area under the concentration-time curve (AUC) targeting. PATIENTS AND METHODS: We collected busulfan concentration-time samples...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Jinjie, Sun, Ning, Feng, Xinying, He, Huan, Mei, Dong, Zhu, Guanghua, Zhao, Libo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894888/ https://www.ncbi.nlm.nih.gov/pubmed/33623415 http://dx.doi.org/10.2147/PGPM.S289834

Ejemplares similares

Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis
por: Feng, Xinying, et al.
Publicado: (2020)

Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
por: Wang, Yang, et al.
Publicado: (2022)

Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats.
por: Saghir, Shakil A, et al.
Publicado: (2002)

Impact of GST thickness on GST-loaded silicon waveguides for optimal optical switching
por: Parra, Jorge, et al.
Publicado: (2022)

Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
por: Gerard, Emma, et al.
Publicado: (2021)

Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
por: Ben Hassine, Khalil, et al.
Publicado: (2021)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Population pharmacokinetics and optimization of the dosing regimen of digoxin in adult patients
por: Komatsu, Toshiaki, et al.
Publicado: (2015)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study
por: Du, Xiaohuan, et al.
Publicado: (2022)

Population pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance
por: Lawson, Rachael, et al.
Publicado: (2022)

Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation
por: Hadjibabaie, M., et al.
Publicado: (2011)

A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients
por: Choe, Sangmin, et al.
Publicado: (2012)

Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing
por: Neroutsos, Efthymios, et al.
Publicado: (2022)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia
por: Shi, Yuan-Yuan, et al.
Publicado: (2023)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis
por: Chen, Chao‐Yang, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization
por: Cao, G, et al.
Publicado: (2013)

Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
por: Nguyen, Ai-Hoc, et al.
Publicado: (2022)

Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients
por: Ansari, M, et al.
Publicado: (2016)

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2019)

Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
por: Chen, Xiao, et al.
Publicado: (2021)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Differential Roles for VviGST1, VviGST3, and VviGST4 in Proanthocyanidin and Anthocyanin Transport in Vitis vinífera
por: Pérez-Díaz, Ricardo, et al.
Publicado: (2016)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Population pharmacokinetic analysis and dosing regimen optimization of penicillin G in patients with infective endocarditis
por: Komatsu, Toshiaki, et al.
Publicado: (2016)

Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa
por: Wagh, Himanshu, et al.
Publicado: (2022)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
por: Bremer, Sara, et al.
Publicado: (2015)

Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients
por: van Hoogdalem, Matthijs W., et al.
Publicado: (2020)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
por: Al-Enezi, Bashayer F., et al.
Publicado: (2023)

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
por: Guidolin, Valeria, et al.
Publicado: (2023)

Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia
por: Zou, Yaru, et al.
Publicado: (2021)

739. Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens
por: Katsube, Takayuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_epbugbage4om80njrdg798v08e